by barry101 | Nov 7, 2023 | Press Releases
HOUSTON, Nov. 7, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses,...
by barry101 | Nov 6, 2023 | Press Releases
– Poster Presented at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting – Annamycin continues to be 100% non-cardiotoxic – Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma...
by barry101 | Oct 11, 2023 | Press Releases
Live video webcast with Walter Klemp, CEO and Jonathan Foster, Executive VP and CFO of Moleculin on Tuesday, October 24th at 12:00 PM ET HOUSTON, Oct. 11, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a...
by barry101 | Oct 2, 2023 | Press Releases
– Phase 1B portion of Phase 1B/2 study demonstrated preliminary CR/CRi rate of 33% (n=6) – Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of AML HOUSTON, Oct. 2, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX)...
by barry101 | Sep 21, 2023 | Press Releases
– Data readouts expected before year end – Previously reported preliminary efficacy data on its Phase 1B/2 clinical trial with Annamycin in monotherapy treatment of STS lung mets with >60% of the subjects exhibiting stable disease after two cycles of...
